# Sung‐Bae Kim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sung-bae-kim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,777 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 74 |
| i10-index | 302 |
| Last Known Institution | University of Ulsan |
| OpenAlex ID | https://openalex.org/A5026459010 |
| ORCID iD | https://orcid.org/0000-0001-5588-8332 |
| Works | 721 |

## Researcher papers

Showing 12 of 14.

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer](https://scholariq.org/papers/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer/)
- [Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy](https://scholariq.org/papers/adjuvant-capecitabine-for-breast-cancer-after-preoperative-chemotherapy/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)
- [Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/trastuzumab-deruxtecan-versus-treatment-of-physician-s-choice-in-patients-with/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Researcher university

- [University of Ulsan](https://scholariq.org/institutions/university-of-ulsan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.